A single dose of doxorubicin-functionalized bow-tie dendrimer cures mice bearing C-26 colon carcinomas
Cameron C. LeeElizabeth R. GilliesMegan E. FoxSteven J. GuillaudeuJean M. J. FréchetEdward E. DyFrancis C. Szoka
635
Citation
46
Reference
10
Related Paper
Citation Trend
Abstract:
The antitumor effect of doxorubicin (DOX) conjugated to a biodegradable dendrimer was evaluated in mice bearing C-26 colon carcinomas. An asymmetric biodegradable polyester dendrimer containing 8-10 wt % DOX was prepared. The design of the dendrimer carrier optimized blood circulation time through size and molecular architecture, drug loading through multiple attachment sites, solubility through PEGylation, and drug release through the use of pH-sensitive hydrazone linkages. In culture, dendrimer-DOX was >10 times less toxic than free DOX toward C-26 colon carcinoma cells after exposure for 72 h. Upon i.v. administration to BALB/c mice with s.c. C-26 tumors, dendrimer-DOX was eliminated from the serum with a half-life of 16 +/- 1 h, and its tumor uptake was ninefold higher than i.v. administered free DOX at 48 h. In efficacy studies performed with BALB/c mice bearing s.c. C-26 tumors, a single i.v. injection of dendrimer-DOX at 20 mg/kg DOX equivalents 8 days after tumor implantation caused complete tumor regression and 100% survival of the mice over the 60-day experiment. No cures were achieved in tumor-implanted mice treated with free DOX at its maximum tolerated dose (6 mg/kg), drug-free dendrimer, or dendrimer-DOX in which the DOX was attached by means of a stable carbamate bond. The antitumor effect of dendrimer-DOX was similar to that of an equimolar dose of liposomal DOX (Doxil). The remarkable antitumor activity of dendrimer-DOX results from the ability of the dendrimer to favorably modulate the pharmacokinetics of attached DOX.Targeted drug delivery
Cite
Citations (162)
Doxorubicin and other anthracycline derivatives play an important role in the treatment of many malignant diseases. Unfortunately, clinical effectiveness of this class of drugs is limited by cumulative cardiotoxicity which occurs in significant percentage of patients at cumulative dose in the range 450-600 mg/m2. Therefore, several strategies have been developed to reduce cardiotoxicity of doxorubicin and its analogues. One of the possible ways leading to the improvement of anticancer selectivity of doxorubicin is the design of polymer and olygomer carriers which may transport drug molecules more efficiently and more specifically. Synthetic polymers are of increasing interest as therapeutic agents owing to their enhanced pharmacokinetic profiles relative to small molecule drugs. Currently a new class of multifunctional polymers is being prepared that can "mask" biologically active compounds, such as cytotoxic agents, until they reach target sites, but which can then release the agent in situ to effect the therapy. The legitimacy of the development of polymer based doxorubicine carriers is supported by the growing number of clinical reports indicating that the use of hydrophilic polymers or polymer coated liposomes as a platform for delivery of the drug results in better therapeutic effects than the free drug. In this article we present the most promising strategies directed at the development of improved anthracycline drugs formulations based of polymer and olygomer carriers. We review: 1) polyethylenoglycol-coated ("pegylated") liposomal doxorubicin; 2) extracellulary tumor-activated prodrugs which are conjugates of doxorubicin with peptides; 3) doxorubicin coated by higly polymerised glycosoaminoglycans; 4) conjugates of doxorubicin with copolymer of N-(2-hydroxypropyl)methacrylamide.
Cardiotoxicity
Cite
Citations (0)
Carrier system
Targeted drug delivery
Cite
Citations (61)
Targeted drug delivery
Biomimetic Materials
Biomimetic Synthesis
Biomimetics
Cite
Citations (154)
Erythrocyte, which is also known as red blood cells, has been extensively studied by scientists for their capability as a potential carrier for the delivery of drugs and drug-loaded microspheres. Resealed erythrocytes, as a drug delivery system has excellent capacity to enhance the therapeutic index and patient compliance. It has got tremendous potential to achieve site specific drug delivery with least wastage of drugs and it also prolong the release of drug. For the preparation of such drug-loaded carrier erythrocytes, the blood samples are simply collected from the organism of interest, and then the erythrocytes are separated from plasma. The drug is entrapped in the erythrocytes, and resealing the resultant cellular carriers. And because of this resealing process these carriers are called resealed erythrocytes. Erythrocytes are biocompatible, biodegradable and the most important advantages are that it possesses long circulation half lives. It can be easily prepared by simple technique and can be loaded along with a variety of biologically active compounds. The present review focuses on the potential applications of erythrocytes in drug delivery.
Blood circulation
Targeted drug delivery
Biocompatible material
Cite
Citations (1)
Vesicular drug delivery system can be defined as highly ordered assemblies consisting of one or more concentric bilayers formed as a result of self-assembling of amphiphilic building blocks in presence of water. Vesicular drug delivery systems are particularly important for targeted delivery of drugs because of their ability to localize the activity of drug at the site or organ of action thereby lowering its concentration at the other sites in body. Vesicular drug delivery system sustains drug action at a predetermined rate, relatively constant (zero order kinetics), efficient drug level in the body, and simultaneously minimizes the undesirable side effects. It can also localize drug action in the diseased tissue or organ by targeted drug delivery using carriers or chemical derivatization. Different types of pharmaceutical carriers such as polymeric micelles, particulate systems, and macro- and micromolecules are presented in the form of novel drug delivery system for targeted delivery of drugs. Particulate type carrier also known as colloidal carrier system, includes lipid particles, micro- and nanoparticles, micro- and nanospheres, polymeric micelles and vesicular systems like liposomes, sphingosomes, niosomes, transfersomes, aquasomes, ufasomes, and so forth.
Niosome
Targeted drug delivery
Carrier system
Cite
Citations (154)
Targeted drug delivery
Cite
Citations (83)
Article de synthese: techniques de microencapsulation et d'incorporation, applications des liposomes polymeriques, exemples de polymeres aux proprietes antithrombiques, application des polymeres comme materiaux d'implantation dans l'appareil cardiovasculaire, en chirurgie orthopedique, etc...
Cite
Citations (3)